Amryt Pharma raising $40m for working capital, acquisitions
8th Dec 2020 09:22
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has entered into agreements to raise $40m, it announced on Tuesday, to fund working capital as well as potential acquisitions and licence deals.
Read moreAmryt shares rise on success of 'EASE' trial
29th Oct 2020 16:09
(Sharecast News) - Biopharmaceutical company Amryt Pharma announced positive results from its pivotal phase 23 'EASE' trial of 'Filsuvez', or 'Oleogel-S10', previously 'AP101', on Thursday.
Read moreAmryt Pharma signs new distribution deal with Swixx BioPharma
19th Oct 2020 08:34
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the signing of a distribution agreement with Swixx BioPharma of Baar, Switzerland on Monday.
Read moreAmryt shares surge on Filsuvez phase 3 results
9th Sep 2020 13:26
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced positive top-line results from its pivotal phase 3 'EASE' trial of 'Filsuvez' for the treatment of dystrophic and junctional epidermolysis bullosa on Wednesday.
Read moreAmryt Pharma upbeat on progress in first nine months of year
5th Nov 2019 11:09
(Sharecast News) - Amryt Pharma updated the market on its trading update for the nine months ended 30 September on Tuesday, noting that it had completed the transaction to acquire Aegerion Pharmaceuticals on 24 September.
Read moreAmryt gets FDA fast track for Oleogel-S10
1st Oct 2019 15:08
(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Tuesday that the US Food and Drug Administration (FDA) has designated the investigation of 'AP101' - Oleogel-S10 - for the treatment of epidermolysis bullosa (EB) as a 'Fast Track' development programme.
Read moreAmryt gets approval to extend EASE trial to infants and children
28th Feb 2019 14:39
(Sharecast News) - Orphan drug company Amryt Pharma updated the market on its phase 3 'EASE' trial for AP101 as a potential treatment for epidermolysis bullosa (EB) on Thursday, reporting that following an assessment by the trial's independent data monitoring committee, it could now enrol infants and children with EB between the ages of 21 days to four years in the trial.
Read moreAmryt Pharma given go-ahead to continue Phase III EASE trial
4th Jan 2019 14:41
(Sharecast News) - Revenue-generating orphan drug company Amryt Pharma announced the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (EB) on Friday.
Read moreAmryt Pharma flags slight delay to EASE trial data
19th Dec 2018 11:22
(Sharecast News) - Orphan drug company Amryt Pharma updated the market on the global AP101 EASE Phase III clinical trial being conducted in patients with Epidermolysis Bullosa (EB) on Wednesday, reporting that the independent data monitoring committee was scheduled to meet on 21 December to review the EASE unblinded interim efficacy analysis results.
Read moreAmryt Pharma scores €8.4m grant from Irish government
10th Dec 2018 16:39
(Sharecast News) - Amryt Pharma announced on Monday that it has secured am €8.4m grant from the Irish Government for three years of development of its AP103 gene therapy platform.
Read moreAmryt Pharma reaches agreement with French authorities over Lojuxta
17th Oct 2018 11:31
(Sharecast News) - Orphan drug company Amryt Pharma has reached agreement with France's Comité économique des produits de santé (CEPS) to reimburse 'Lojuxta' (lomitapide) for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH) in France.
Read moreAmryt Pharma secures €20m loan from European Investment Bank
2nd Dec 2016 08:07
(ShareCast News) - AIM-listed Amryt Pharma has secured a €20m loan from the European Investment Bank to secure its near and mid-term funding for its gel product and a development for a drug compound compound. The loan secures funding for its product Episalvan, which treats skin disorder Epidermolysi
Read moreAmryt Pharma's drug compound gains FDA approval
7th Nov 2016 12:19
(ShareCast News) - The US Food and Drug Administration (FDA) has granted orphan drug designation to AIM-listed Amryt Pharma's drug compound which has the potential to treat acromegaly. The drug compound, AP102, now qualifies for tax credits for qualified clinical trials and market exclusivity on reg
Read moreAmryt Pharma positive about drug developments
13th Sep 2016 16:10
(ShareCast News) - Clinical stage specialty pharma company focused on best in class treatments for orphan diseases, Amryt Pharma, posted its interim financial statements for the six months to 30 June on Tuesday. The AIM-traded firm was admitted to trading on AIM and the ESM market of the Irish Stock
Read moreAmryt Pharma reverses onto AIM to advance orphan drug strategy
19th Apr 2016 12:05
(ShareCast News) - Speciality drug developer Amryt Pharma has completed its flotation via the reverse takeover of AIM-listed Fastnet, raising £10m of new cash in the process and acquiring two operating companies. As part of the float, Amryt acquired drug German drug development and manufacturing com
Read more